Ticker brief
JNJ JOHNSON & JOHNSON
Consumer, Non-cyclical · Pharmaceuticals
last close
$268.04
1 day
+0.9%
14 days
+3.0%
mkt cap
$633.2B
signals 14d
62
authors 14d
52
crowd 14d
+0.8σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 23% mid · 77 pctile own 1y | IV/HV 0.94× (as of 2026-08-06) |
| Skew — 25Δ RR 30d | -0.028 50 pctile own 1y | balanced vs own range |
| Net dealer OI (NDOI) | +0.50 normal | 5-session Δ +0.01 (as of 2026-07-06) |
| OI alarm | quiet | last alarm 2026-01-21 (z=2.3) |
| Next earnings | 2026-10-13 | in 46d |
Sentiment — last 14 days
daily mean sentiment, 2026-08-15 → 2026-08-28 · now +0.38 (−1 bearish … +1 bullish)
Who spoke52
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @bioinvestor24 | A | -0.45 | 4 | -0.01 |
| @DivIncomeBcast | C | +0.27 | 3 | +0.35 |
| @Div_Croissant | C | +1.57 | 2 | +0.32 |
| @SpartanTrading | C | -1.46 | 2 | +0.40 |
| @kpak82 | C | -0.13 | 2 | -0.67 |
| @StockMarketNerd | A | +1.53 | 2 | +0.10 |
| @BottomPhishing | B | -1.20 | 2 | +0.30 |
| @TalkMarkets | C | · | 1 | +0.45 |
| @investseekers | B | -0.65 | 1 | +0.10 |
| @AponiaAnalytics | B | +4.91 | 1 | -0.10 |
| @bugra_kurtoglu | C | +1.08 | 1 | +0.20 |
| @johnscharts | C | -2.20 | 1 | +0.40 |
| @Globalmess65 | C | -1.00 | 1 | +0.25 |
| @BeatTheBotz | C | -0.87 | 1 | +0.40 |
| @stageanalysis | C | +0.85 | 1 | +0.35 |
| @PythiaR | A | -0.07 | 1 | +0.60 |
| @tastyliveshow | B | +0.08 | 1 | -0.15 |
| @akishore | C | -1.38 | 1 | +0.45 |
| @OptionsFlowBoss | C | · | 1 | +0.35 |
| @AryaFintech | C | -1.31 | 1 | +0.15 |
| @StockWorthyApp | C | +0.41 | 1 | +0.00 |
| @RockyTSTH | C | · | 1 | +0.55 |
| @cajurite | C | -0.99 | 1 | +0.70 |
| @BeyondOption | B | · | 1 | +0.45 |
| @Trent_TACap | B | -0.04 | 1 | +0.65 |
Recent signals30of 62 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @CHItrader | +0.50 | FDA approved JNJ's Stelara for children age two and older with ulcerative colitis. | — | tweet ↗ |
| 2026-08-28 | @bioinvestor24 | +0.00 | Frames SYRE as a broad platform positioned to compete with major immunology companies and exceed peer disease breadth. | — | tweet ↗ |
| 2026-08-28 | @BiotechCH | +0.50 | JNJ received a label expansion for Imaavy 16 months after approval. | — | tweet ↗ |
| 2026-08-28 | @semodough | +0.50 | Reports Chinese regulatory approval of icotyde for moderate-to-severe plaque psoriasis. | — | tweet ↗ |
| 2026-08-27 | @bioinvestor24 | -0.35 | Questions extreme therapy pricing while comparing costs and revenue burdens across several drug makers. | +0.9% | tweet ↗ |
| 2026-08-26 | @PolycarpFX | +0.00 | Flags a large recent IXJ print and notes the ETF is extended on short time frames. | -0.7% | tweet ↗ |
| 2026-08-25 | @fwpharma | +0.50 | FDA cleared J&J's Imaavy as the first treatment for a rare blood disorder. | -1.9% | tweet ↗ |
| 2026-08-24 | @snorlax_uw | +0.00 | Explains ex-dividend arbitrage-related call flow and expected open-interest declines. | -1.8% | tweet ↗ |
| 2026-08-24 | @USAnt_IDEA | +0.55 | Identifies rotation from technology into financials, materials, pharma and beauty | -1.8% | tweet ↗ |
| 2026-08-24 | @TheNewMoney_app | +0.00 | Lists notable single-stock options-flow names without directions in the text. | -1.8% | tweet ↗ |
| 2026-08-24 | @CapitalFlowApp | +0.65 | Reports more than $12.4 million in JNJ call flow tied to FDA approvals and settlement progress. | -1.8% | tweet ↗ |
| 2026-08-24 | @HostileCharts | +0.15 | Flags JNJ as a non-tech chart idea, but the setup is only visible in media. | -1.8% | tweet ↗ |
| 2026-08-23 | @ElliottForecast | +0.85 | Author expects JNJ to continue rallying toward 271.37 or higher. | -0.8% | tweet ↗ |
| 2026-08-23 | @BottomPhishing | +0.25 | Broad market review argues Friday's bounce lacked volume and growth remains pressured by yields. | -0.8% | tweet ↗ |
| 2026-08-23 | @BottomPhishing | +0.35 | Interprets Dow leadership by healthcare as money rotating away from growth. | -0.8% | tweet ↗ |
| 2026-08-22 | @TheETFTracker | +0.00 | Lists DGRO's top holdings and portfolio weights. | -0.8% | tweet ↗ |
| 2026-08-21 | @KeithTradeSmith | +0.55 | Highlights large annual gains and confirmed Stage 2 breakouts in three blue chips. | -0.8% | tweet ↗ |
| 2026-08-21 | @MikeJTrades | +0.20 | Market digest reports index moves and company catalysts including MRNA data and TSLA robotaxi authorization. | -0.8% | tweet ↗ |
| 2026-08-21 | @SpartanTrading | +0.80 | Lists completed call-option results; output is capped at the first six distinct successful tickers. | -0.8% | tweet ↗ |
| 2026-08-21 | @IngJuanPa7 | -0.30 | Reports an adverse federal ruling for JNJ in litigation over a talc study. | -0.8% | tweet ↗ |
| 2026-08-21 | @PeloSwing | +0.15 | Reports JNJ net options flow spiking; the unrelated headline is not a company event. | -0.8% | tweet ↗ |
| 2026-08-21 | @DivIncomeBcast | +0.45 | Presents six companies as a basket of rock-solid dividend stocks backed by quality attributes. | -0.8% | tweet ↗ |
| 2026-08-21 | @KoujiSato19 | +0.60 | Promotes a bullish JNJ earnings analysis focused on growth, oncology, MedTech restructuring and dip buying. | -0.8% | tweet ↗ |
| 2026-08-20 | @ttvresearch | +0.00 | Infographic ranks year-to-date performance of Dow components; individual values require the chart. | +0.3% | tweet ↗ |
| 2026-08-20 | @StableBread | +0.05 | Presents RVPH as deeply undervalued despite delays, citing patent extension and possible TEVA strategic interest. | +0.3% | tweet ↗ |
| 2026-08-20 | @DivIncomeBcast | +0.35 | Reports JNJ up 32% YTD and positive in eight of the last eleven sessions. | +0.3% | tweet ↗ |
| 2026-08-19 | @bioinvestor24 | +0.30 | Frames personalized mRNA cancer vaccines as a massive opportunity for large pharma. | -2.0% | tweet ↗ |
| 2026-08-19 | @TheMarket_Monk | +0.65 | States that major healthcare stocks are breaking out. | -2.0% | tweet ↗ |
| 2026-08-19 | @LaMonicaBuzz | +0.30 | Moderna gained 170% while several other pharma and biotech stocks reached records. | -2.0% | tweet ↗ |
| 2026-08-19 | @EmmanuelInvest | +0.20 | Lists healthcare names at fresh 52-week highs, capped at six tickers. | -2.0% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.